M&A Deal Summary |
|
|---|---|
| Date | 2025-02-25 |
| Target | Organovo - FXR program |
| Sector | Life Science |
| Buyer(s) | Lilly |
| Sellers(s) | Organovo |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1876 |
| Sector | Life Science |
| Employees | 43,000 |
| Revenue | 34.1B USD (2023) |
Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
| DEAL STATS | # |
|---|---|
| Overall | 35 of 35 |
| Sector (Life Science) | 28 of 28 |
| Type (Divestiture) | 7 of 7 |
| State (California) | 11 of 11 |
| Country (United States) | 30 of 30 |
| Year (2025) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-12-30 |
Eli Lilly - Huminsulin
Indianapolis, Indiana, United States Eli Lilly's Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children. |
Sell | - |
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Life Science |
| Employees | 12 |
| Revenue | 1M USD (2022) |
Organovo is a developer of 3-D bioprinted tissues comprised of human cells. Organovo focuses on utilizing its tissues for disease modeling and drug discovery, with the therapeutic liver tissue development on hold pending additional advances. Organovo was founded in 2007 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| State (California) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2025) | 1 of 1 |
